# EDGAR Filing Document

**Accession Number:** 0000882095
**File Stem:** 0001104659-26-061317
**Filing Date:** 2026-5
**Character Count:** 7537
**Document Hash:** b92b8975d00087529bca194d4e0b9cdb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-061317.hdr.sgml**: 20260514

**ACCESSION NUMBER**: 0001104659-26-061317

**CONFORMED SUBMISSION TYPE**: FWP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260514

**DATE AS OF CHANGE**: 20260514

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GILEAD SCIENCES, INC.
- **CENTRAL INDEX KEY:** 0000882095
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 943047598
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** FWP
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-273745
- **FILM NUMBER:** 26980375

**BUSINESS ADDRESS:**
- **STREET 1:** 333 LAKESIDE DR
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404
- **BUSINESS PHONE:** 6505743000

**MAIL ADDRESS:**
- **STREET 1:** 333 LAKESIDE DR
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GILEAD SCIENCES INC
- **DATE OF NAME CHANGE:** 19930328
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GILEAD SCIENCES, INC.
- **CENTRAL INDEX KEY:** 0000882095
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 943047598
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** FWP

**BUSINESS ADDRESS:**
- **STREET 1:** 333 LAKESIDE DR
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404
- **BUSINESS PHONE:** 6505743000

**MAIL ADDRESS:**
- **STREET 1:** 333 LAKESIDE DR
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GILEAD SCIENCES INC
- **DATE OF NAME CHANGE:** 19930328

**Free Writing Prospectus**

**Filed Pursuant to Rule 433**

**Registration Statement No. 333-273745**

**May 14, 2026**

**GILEAD SCIENCES, INC.**

![](tm2531124d3_fwpimg001.jpg)

<u>PRICING TERM SHEET</u>

4.250% SENIOR NOTES DUE 2028

4.400% SENIOR NOTES DUE 2029

4.600% SENIOR NOTES DUE 2031

4.900% SENIOR NOTES DUE 2034

---

| | |
|:---|:---|
| **Issuer:** | Gilead Sciences, Inc. (the "Company")<br>|
| **Title of Security:** | 4.250% Senior Notes due 2028 (the "2028 Notes")<br> 4.400% Senior Notes due 2029 (the "2029 Notes")<br> 4.600% Senior Notes due 2031 (the "2031 Notes")<br> 4.900% Senior Notes due 2034 (the "2034 Notes")<br>|
| **Principal Amount:** | 2028 Notes: $500,000,000<br> 2029 Notes: $1,000,000,000<br> 2031 Notes: $1,000,000,000<br> 2034 Notes: $500,000,000<br>|
| **Trade Date:** | May 14, 2026<br>|
| **Settlement Date:** | May 20, 2026 (T+4)<br>*It is expected that delivery of the notes will be made against payment therefor on or about May 20, 2026, which is the fourth business day following the date of the pricing of the notes (T+4). Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in one business day unless the parties to that trade expressly agree otherwise. Accordingly, purchasers who wish to trade the notes on or after the date of pricing but prior to the closing date may be required, by virtue of the fact that the notes initially will settle in T+4, to specify an alternative settlement cycle at the time of any such trade to prevent failed settlement and should consult their own advisers.* |

---

---

| | |
|:---|:---|
| **Maturity Date:** | 2028 Notes: May 20, 2028<br> 2029 Notes: May 20, 2029<br> 2031 Notes: May 20, 2031<br> 2034 Notes: May 20, 2034 |
| <br> **Price to Public:** | <br> 2028 Notes: 99.958% of the principal amount<br> 2029 Notes: 99.981% of the principal amount<br> 2031 Notes: 99.996% of the principal amount<br> 2034 Notes: 99.987% of the principal amount<br>|
| **Yield to Maturity:** | 2028 Notes: 4.272%<br> 2029 Notes: 4.407%<br> 2031 Notes: 4.601%<br> 2034 Notes: 4.902% |
| <br> **Spread to Benchmark Treasury:** | <br> 2028 Notes: 28 basis points<br> 2029 Notes: 38 basis points<br> 2031 Notes: 48 basis points<br> 2034 Notes: 45 basis points |
| <br> **Benchmark Treasury:** | <br> 2028 Notes: 3.750% due April 30, 2028<br> 2029 Notes: 3.875% due April 15, 2029<br> 2031 Notes: 3.875% due April 30, 2031<br> 2034 Notes: 4.125% due February 15, 2036 |
| **Benchmark Treasury Price / Yield:** | 2028 Notes: 99-17+ / 3.992%<br> 2029 Notes: 99-18 ⅝ / 4.027%<br> 2031 Notes: 98-29 / 4.121%<br> 2034 Notes: 97-13 ¾ / 4.452% |
| <br> **Interest Payment Dates:**  | <br> 2028 Notes: May 20 and November 20, commencing November 20, 2026<br> 2029 Notes: May 20 and November 20, commencing November 20, 2026<br> 2031 Notes: May 20 and November 20, commencing November 20, 2026<br> 2034 Notes: May 20 and November 20, commencing November 20, 2026 |
| **Optional Redemption:** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Make-Whole Call:**<br>| 2028 Notes: T+5 basis points, prior to May 20, 2028<br> 2029 Notes: T+10 basis points, prior to April 20, 2029 (assuming the notes called for redemption matured on April 20, 2029)<br> 2031 Notes: T+10 basis points, prior to April 20, 2031 (assuming the notes called for redemption matured on April 20, 2031)<br> 2034 Notes: T+10 basis points, prior to March 20, 2034 (assuming the notes called for redemption matured on March 20, 2034) |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Par Call:**<br>| 2028 Notes: N/A (Make-Whole Call only)<br> 2029 Notes: At 100%, on or after April 20, 2029<br> 2031 Notes: At 100%, on or after April 20, 2031<br> 2034 Notes: At 100%, on or after March 20, 2034<br>|
| **CUSIP / ISIN:** | 2028 Notes: 375558 CJ0 / US375558CJ09<br> 2029 Notes: 375558 CK7 / US375558CK71<br> 2031 Notes: 375558 CL5 / US375558CL54<br> 2034 Notes: 375558 CM3 / US375558CM38<br>|
| **Day Count Convention:** | 360-day year consisting of twelve 30-day months<br>|
| **Joint Book-Running Managers:** | Barclays Capital Inc.<br> BofA Securities, Inc.<br> Citigroup Global Markets Inc.<br> Goldman Sachs & Co. LLC<br> HSBC Securities (USA) Inc.<br> J.P. Morgan Securities LLC<br> Mizuho Securities USA LLC<br> Morgan Stanley & Co. LLC<br> RBC Capital Markets, LLC<br> SG Americas Securities, LLC<br> TD Securities (USA) LLC<br> U.S. Bancorp Investments, Inc.<br> Wells Fargo Securities, LLC<br>|
| **Co-Managers:** | Blaylock Van, LLC<br> CastleOak Securities, L.P.<br> Independence Point Securities LLC<br> Samuel A. Ramirez & Company, Inc.<br> Siebert Williams Shank & Co., LLC |

---

**\* \* \***

**The issuer has filed a registration statement (including a prospectus) and a prospectus supplement with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement, the prospectus supplement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Barclays Capital Inc. toll-free at 1-888-603-5847, calling BofA Securities, Inc. toll free at 1-800-294-1322 or calling Citigroup Global Markets Inc. toll-free at 1-800-831-9146.**

**This pricing term sheet supplements the Preliminary Prospectus Supplement filed by Gilead Sciences, Inc. on** **May 14, 2026 relating to its Prospectus dated August 4, 2023.**